The availability of new medications approved by the U.S. Food & Drug Administration to treat ankylosing spondylitis (AS), as well as new evidence on tapering and discontinuing biologics, magnetic resonance imaging and radiograph imaging were the driving forces behind the release of a revised treatment guideline for AS and non-radiographic axial spondyloarthritis in 2019. In this resource center, you’ll find our summary of the guideline, as well as research reviews, case reports and clinical articles on advances in the diagnosis and management of axial spondyloarthritis.
FEATURED ARTICLE: Data Accumulate to Suggest HLA-B27 Status May Drive Axial Phenotype in SpA